Abstract Number: PB0208
Meeting: ISTH 2020 Congress
Background: Oral factor Xa inhibitors such as Apixaban, betrixaban, edoxaban and rivaroxaban are widely used for the management of thrombotic and cardiovascular indications. Andexanet alfa (AA) is approved for the management of bleeding complications with apixaban and rivaroxaban.
Aims: This study is designed to compare the neutralization efficacy of andexanet alfa for various factor Xa inhibitors in clot-based and anti-Xa assays.
Methods: Citrated pooled plasma was prepared from individual donors. Active pharmaceutical ingredients version of various factor Xa inhibitors were commercially obtained. Each of the factor Xa inhibitor was supplemented in plasma in the concentration range of 0 – 1 ug/ml. The neutralization profile of AA was studied at 100ug/ml and 200ug/ml and saline was used as a control. Clot-based PT, aPTT and amidolytic anti-Xa assays. The IC50 for the Xa inhibitory activity were calculated for the control drugs and after supplementation with AA. The neutralization profile in the clot-based assays was measured in terms of decrease in clotting times.
Results: Apixaban and edoxaban exhibited similar inhibitory profiles in the anti-Xa assays, where as rivaroxaban and betrixaban exhibited much higher IC50s. AA effectively neutralized the anticoagulant effects of all agents at both the 100 and 200 ug/ml, however the neutralization profile in the clot based was not proportional to the anti-Xa effects. At 200ug/ml only betrixaban was completely neutralized whereas all the other agents were partially neutralized. The order of neutralization at 200ug/ml was betrixaban > rivaroxaban > apixaban > edoxaban.
Conclusions: These studies show that the neutralization profiles of various Xa agents by AA exhibit differential characteristic response for each of the individual agent. These results indicate that individual dosing based on clinical endpoints for each agent rather than the neutralization of anti-Xa activity measurement may be more relevant to the clinical outcome.
To cite this abstract in AMA style:Siddiqui F, Tafur A, Hoppensteadt D, Bontekoe E, Jeske W, Lewis B, Fareed J. Discordance Between the Neutralization Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban in the Clotting Assays and Anti-Xa Measurements [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/discordance-between-the-neutralization-profile-of-apixaban-betrixaban-edoxaban-and-rivaroxaban-in-the-clotting-assays-and-anti-xa-measurements/. Accessed November 30, 2021.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/discordance-between-the-neutralization-profile-of-apixaban-betrixaban-edoxaban-and-rivaroxaban-in-the-clotting-assays-and-anti-xa-measurements/